Ropes & Gray Logo
Page Translations
Iain Fox

Iain Fox

Associate
Areas of Practice
  • *
Jump to:

Iain Fox is an associate in Ropes & Gray’s corporate department, advising clients on M&A and venture capital transactions. 

Iain has experience acting for corporate venture corporations, financial investors as well as start-ups on a range of issues, including acquisitions, disposals, equity investments, management incentivisation and providing general corporate law advice.

Iain trained at the firm’s London office, gaining experience in the strategic transactions, life sciences, data, privacy, and cybersecurity, and asset management teams.

Experience

Mergers and Acquisitions

  • Advised a global pharmaceutical company on its acquisition of an oncology spin-out from a British university.
  • Advised Ecovyst Inc. in an agreement to acquire the Calabrian sulfur dioxide and related sulfur derivatives business from INEOS Enterprises.
  • Advised Partners Group on its acquisition of a majority stake in FairJourney Biologics, a leading antibody discovery contract research organisation, from GHO Capital Partners.
  • Advised TPG’s The Rise Fund on its agreement with Stirling Square Capital Partners to acquire a majority investment in Outcomes First Group.
  • Advised Population Health Partners on the formation of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic disease, on a $290 million financing, a licensing of assets from D&D Pharmatech and the acquisition of a spin-out from Imperial College London.
  • Advised K2 Insurance Services on the establishment and formation of new insurance underwriting teams.
  • Advised a US investment firm on the sale of its minority shareholding in an insurance company.

Venture Capital

  • Advised Basecamp Research, a frontier AI lab harnessing evolution to design new medicines, in connection with:
    • its investment from NVentures (NVIDIA's venture capital arm) in its pre-Series C round; and
    • its $140 million Series C financing.
  • Advised Pfizer on its participation in CellCentric's $220 million Series D financing.
  • Advised Johnson & Johnson Innovation – JJDC, Inc. as lead investor in the US$40 million Series A financing of Cellular Origins, a UK company developing robotic automation for cell therapy manufacturing.
  • Advised a global pharmaceutical company on its participation in the convertible loan note and Series C financing of a UK oncology biotech.
  • Advised a UK-based biotechnology company on its seed financing round, backed by a syndicate of international venture capital investors and leading UK charities.
  • Advised a global asset manager on its investment in a UK AI infrastructure company and the company's subsequent redomiciliation to the US.
  • Advised a global asset manager on its investment in a leading UK AI video generation platform.
  • Advised the corporate venture arm of a global healthcare company on financings of French medtech and cell therapy manufacturing companies.
  • Advised a global semiconductor company on its strategic investments into an early-stage AI computing company, including a SAFE financing.
  • Advised the corporate venture arm of a European pharmaceutical company on its investment in a UK biotech company's seed extension round.
  • Advised a US life sciences venture investor on convertible loan note and equity investments in UK biotech and cell therapy technology companies.
  • Advised a global reinsurer on its strategic minority investments in insurtech and sustainability software companies.
  • Advised a US investor on its convertible loan note and equity investments in a UK energy company.
  • Advised Fraiya on its spin-out and Series Seed financing.

Areas of Practice

    Disclaimer
    Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).